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Purpose: To compare the value of serum biomarkers, FGF21 and GDF15 with histological 
analysis of muscle in the diagnosis of mitochondrial disease. 
Methods: We collected 194 serum samples from patients with a suspected or known 
mitochondrial disease. Biomarkers were analyzed blinded using enzyme labelled immunosorbent 
assay (ELISA). Clinical data was collected using a structured questionnaire. 
Results: Only 39% of patients with genetically verified mitochondrial disease had mitochondrial 
pathology in their muscle histology. In contrast, biomarkers were elevated in 62% of patients 
with genetically verified mitochondrial disease. Those with both biomarkers elevated had a 
muscle manifesting disorder and a defect affecting mitochondrial DNA expression. If at least one 
of the biomarkers was induced and the patient had a myopathic disease, a mitochondrial DNA 
expression disease was the cause with 94% probability.  
Among patients with biomarker analysis and muscle biopsy taken <12 months apart, a 
mitochondrial disorder would have been identified in 70% with analysis of FGF21 and GDF15 
compared to 50% of patients whom could have been identified with muscle biopsy alone. Muscle 
findings were non-diagnostic in 72% (children) and 45% (adults).   
Conclusion: Induction of FGF21 and GDF15 suggest a mitochondrial etiology as an underlying 
cause of a muscle manifesting disease.  Normal biomarker values do not, however, rule out a 
mitochondrial disorder, especially if the disease does not manifest in muscle. We suggest that 
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FGF21 and GDF15 together should be first-line diagnostic investigations in mitochondrial 
disease complementing muscle biopsy.  
 
Synopsis 
Analysis of serum biomarkers should be used in first-line mitochondrial disease diagnostics; they 
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Mitochondrial disorders are genetic disorders characterized by defects in oxidative 
phosporylation which arise from defects in either the mitochondrial or nuclear genome that 
impair mitochondrial function.1 They are progressive diseases often presenting in skeletal muscle, 
but also affecting organs such as the brain, endocrine organs, liver, heart and sensory organs. The 
prevalence of these diseases has been estimated to be 1/2000-1/10 000 live births making them 
among the most common inherited metabolic disorders.2-6 Despite involvement of the same 
intracellular organelle, mitochondrial diseases are highly heterogeneous in both clinical 
manifestations and genetic basis:  currently, more than 250 genes have been identified (The 
Mitochondrial Disease Sequence Data Resource Consortium, MSeqDR, https://mseqdr.org/). 
 
Despite next generation sequencing (NGS) techniques with improved efficacy of establishing a 
genetic diagnosis, patients with suspected mitochondrial disease often undergo a muscle biopsy 
to look for presence of cytochrome c oxidase (COX) deficient fibers or defect in oxidative 
phosphorylation (OXPHOS) enzyme activities. Other biomarkers, including blood lactate, 
pyruvate, their ratio and creatine kinase have been used, but these lack both sensitivity and 
specificity.7 
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Two novel serum biomarkers, fibroblast growth factor 21 (FGF21),7,8 and growth differentiation 
factor 15 (GDF15)9,10 have been reported. The efficacy of these biomarkers compared to the 
traditional biomarkers in diagnosing muscle-manifesting mitochondrial disorders has been 
replicated in several studies.11-19 FGF21 is a metabolic cytokine that is upregulated in the liver 
during fasting to induce lipolysis in adipose tissue of healthy individuals.20 GDF15 is a member 
of the transforming growth factor beta (TGF-β) superfamily, also secreted by the liver, especially 
in response to liver tissue injury.21 In mitochondrial myopathy, which is a genetic disorder 
leading to OXPHOS defect affecting predominantly, but not exclusively, skeletal muscle,22 
FGF21 and GDF15 are expressed in skeletal muscle together with OXPHOS defect.7-9 In 
diseased muscle, FGF21 is part of mitochondrial integrated stress response, together with major 
metabolic remodeling of the tissue.23,24 Both cytokines are induced in mice and humans with 
mitochondrial myopathy, but also in some non-mitochondrial metabolic (FGF21) and 
degenerative/endstage (GDF15) conditions.25,26 However, in the case of FGF21, mitochondrial 
myopathy is the only condition, in which secretion of FGF21 is directly linked to a monogenic 
defect.15 GDF15, however, has also been reported to be elevated in for example chronic 
obstructive pulmonary disease (COPD),27 ovarian cancer,28 and diabetes.29 In addition, it has 
been described to be a predictive biomarker for cardiovascular disease mortality.30 
 
We reported recently that both FGF21 and GDF15 are greatly induced in mitochondrial 
myopathies caused by mitochondrial DNA (mtDNA) expression disorders (mtDNA deletions 
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that remove tRNA genes, mitochondrial maintenance and  mitochondrial translation defects), but 
not in defects directly affecting mitochondrial OXPHOS subunits or respiratory chain complex 
assembly.15 Both biomarkers correlate to muscle involvement.10,13,31 Comparative studies of 
these biomarkers to muscle histology or OXPHOS activity findings are limited, as is our 
understanding of how these biomarkers respond to mitochondrial disorders affecting the central 
nervous system.  
The aims of this study were to clarify the performance of FGF21 and GDF15 compared to 
conventional diagnostic means, muscle histology and biochemical OXPHOS activity 
measurement in a prospective setting, and to study whether biomarkers could sometimes replace 
the need for invasive muscle biopsy in the diagnostics of mitochondrial diseases.   
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Patient data and samples: 
The study was conducted in five North European centers within the Mitochondrial Clinical 
Research Network between 2009-2016. Participating centers were Finland (Helsinki and Oulu), 
Sweden (Gothenburg), the Netherlands (Rotterdam) and Norway (Bergen). Detailed clinical data 
was collected between April 2013 and February 2017 using an electronic questionnaire designed 
for this study. The clinical data included age, gender, specific clinical features, biochemical 
testing and histology of the muscle.  The data on the genetic etiology was finalized in March 
2018. Symptomatic patients with a clinical suspicion of mitochondrial disease were recruited to 
the study, and 173 patients were enrolled.  
 
Muscle biopsy samples were analyzed as part of the patients’ routine diagnostic evaluation, and 
serum samples were collected for FGF21 and GDF15 analysis. Histological analysis of the 
muscle alone or with biochemical analysis was performed based on each center’s diagnostic 
pathway.  Genetic studies were performed in each center by their routine diagnostic pathway. 
Figure 1 summarizes the patient categorization flowchart. Samples were considered as 
prospective when taken prior to the establishment of a genetic diagnosis. Of the 173 prospective 
patients, 46 (26%) received a genetic and 22 (13%) a non-genetic diagnosis during the study 
period while 105 patients (61%) remained without specific diagnosis. Twenty-one patients were 
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also included retrospectively. They were patients, who had had a clinical suspicion of 
mitochondrial disease, and their genetic diagnosis had been identified (Figure 1). The age of the 
patients varied from 0 to 79 years, of which 45 % were children. There was a slight female 
preponderance (110 females; 84 males). Clinical characteristics are shown in Table 1. Eight 
patients had diabetes, nine had cardiac and none had renal manifestation. 
 
The FGF21 and GDF15 values were expected to reflect best the skeletal muscle pathology when 
the time between muscle and serum sampling was not more than 6 (children) or 12 (adults) 
months. In 68 patients, muscle biopsy was either not taken, or the time elapsed between serum 
sampling and muscle biopsy was >6-12 months, excluding proper comparison of the muscle 
disease severity and the biomarker concentrations. Since small amounts of cytochrome-c-oxidase 
(COX, OXPHOS complex IV) negative fibers are known to accumulate with age, we considered 
a finding of <1% of COX-negative fibers in people over 50 years of age not to be associated with 
mitochondrial pathology. 
 
The muscle data collected for this study included presence of COX deficient fibers and ragged 
red fibers, the typical findings of mitochondrial myopathies, as well as the amount of glycogen 
and lipids, description of histology and suggested diagnosis. OXPHOS analysis was classified 
abnormal if the activity of enzyme complexes, oxygen consumption (polarography) and/or ATP 
synthesis activities were decreased (below normal range).  
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Serum biomarker analyses: 
The serum samples were snap-frozen and stored at -80 oC before analysis. The biomarkers were 
analyzed with commercially available ELISA-kits (FGF21: Biovendor, Brno, Czech Republic; 
the results exceeding the linear range were replicated with the kit of R&D Systems, Minneapolis, 
MN. GDF15: R&D Systems) according to the manufacturers’ instructions. The plate 
absorbances were measured using a SpectraMax 190 absorbance microtiter plate reader 
(Molecular Devices, Sunnyvale, CA). 
 
Statistical analyses:  
Causative mutations involved in a gene that encodes a protein known to be associated with 
mitochondrial OXPHOS function or structure, were considered mitochondrial diseases. The 
pediatric cohort consisted of all those subjects sampled before 16 years of age. The odds ratios 
were calculated using Fisher’s exact test. Association of FGF21 values to GDF15 values was 
done using Spearman’s rank correlation analysis. Association was considered significant if the r-
value exceeded 0.5 and two-sided p-value was <0.05. In this case, a linear regression model was 
performed and the R2 and P-values for goodness of fit are reported. All statistical analyses were 
performed with PRISM 8.4.3 (Graph Pad software, La Jolla, CA). 
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We determined serum FGF21 and GDF15 values in altogether 194 patients, of which 88 were 
children and 106 adults. FGF21 and GDF15 values correlated significantly to each other (n=194, 
r=0.5, p<0.0001, R2=0.09, p<0.0001). The cut-off values for both biomarkers were chosen 
according to our previous study: the 95th percentile of controls (for FGF21 331 pg/ml and for 
GDF15 1014 pg/ml) and 95th percentile of patients with non-mitochondrial myopathies (for 
FGF21 591 pg/ml and for GDF15 2581 pg/ml).14 Based on  these cut-offs, we determined the 
following concentration categories: Low (FGF21 < 331 pg/ml and GDF15 < 1014 pg/ml), 
intermediate (FGF21 331-591 pg/ml and GDF15 1014-2581 pg/ml), and high (FGF21 >591 
pg/ml and GDF15 >2581 pg/ml).  
 
Forty-two patients had a known genetic cause for their disease (genetically verified 
mitochondrial disease), and 62% (n=26/42) of these fell into the intermediate or high category 
(Table 2A), whereas only 19% (n=9/47) of patients with non-mitochondrial disease (genetically 
or clinically) showed such values (Table 2B and Supplementary table 1).  
 
The odds ratio (OR) for having a mtDNA expression disorder was 48 (n=25, CI 4.368-567.7, 
p=0.001), if at least one of the biomarkers showed intermediate or high concentrations in a 
(clinically) muscle manifesting disorder.  If at least one of the biomarkers was induced 
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(intermediate or high) in a patient with (clinically) myopathic disease, an mtDNA expression 
disease was the cause with 94% probability (CI 0.7302-0.9970, p<0.01, positive predictive 
value). Patients with elevated biomarker values without a verified genetic diagnosis showed 
more symptoms and findings suggestive of mitochondrial myopathy (progressive external 
ophthalmoplegia, COX deficient fibers, OXPHOS defect) (Supplementary table 2A) than those 
who had at least one of the biomarkers in the low range (Supplementary table 2B-C). 
 
Of all 194 patients, 26 patients had both biomarkers elevated, and of those, 50% had genetically 
verified mitochondrial disease. 27 patients had a single biomarker elevated, and of those 48 % 
had genetically verified mitochondrial disease (Table 3 and Supplementary tables 1 and 2). 
 
Findings in patients with genetically verified mitochondrial diseases  
Table 3 summarizes biomarker, clinical and muscle biopsy findings in patients with genetically 
verified mitochondrial diseases of whom 13/42 had both elevated GDF15 and FGF21 
concentrations. They belonged to the following categories: muscle phenotype (clinical, 
histopathological or biochemical) or defect affecting mtDNA expression (Table 3A).  
Eighty-two percent of mitochondrial patients who had clinically manifesting muscle disorder 
showed elevation of biomarkers, whereas only 65% of them showed mitochondrial pathology in 
muscle biopsy sample (no muscle sample from two patients). Forty three percent of patients with 
a genetically verified mitochondrial disease had low GDF15 and FGF21 concentrations (Table 
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3C).  These patients belonged to the categories: non-myopathic phenotypes, genetic defects 
affecting OXPHOS subunits or assembly, or genetic defects not directly affecting OXPHOS. 
There were however three exceptions: two patients had mitochondrial tRNALeu(UUR) (MTTL1) 
mutation (m.3243A>G) and myopathy, and the third patient had a mutation in mitochondrial 
methionyl-tRNA formyltransferase (MTFMT) and exercise intolerance. Six patients with non-
OXPHOS disease (and mutations in SLC19A3, ADD3, AMARC, DNAJC19 and ATP1A3, as well 
as a deletion in chromosome 20p) had elevated biomarker values (Table 2B).  
 
 
164 patients with muscle biopsy findings  
Altogether 164 patients underwent muscle biopsy. Twenty percent of patients had histological 
findings suggestive of mitochondrial myopathy, and in these all but one genetically verified 
disorders were mitochondrial. Sixty-six percent of patients showed no or unspecific changes in 
muscle histology analysis, and 4% of samples were excluded due to poor quality. Among 
patients with genetically verified mitochondrial disorders, 39% had mitochondrial myopathy 
based on histological assessment, and 54% of them remained without diagnostic findings (Figure 
2E-G). 
 
127 Patients whose muscle biopsy and serum sample were taken less than 6-12 months apart  
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In patients having muscle biopsy and serum samples been taken <6-12 months apart, we 
compared the biomarker concentrations with muscle histology findings (no OXPHOS activity 
analysis included) (n=127, Figure 2A-D). If both biomarkers were induced (n=14), 57% had a 
diagnostic muscle sample (36% mitochondrial myopathy, 21% other disease, eg. inflammatory 
myopathy). If only FGF21 was induced (intermediate or high, n=12), 50% had normal muscle 
histology, whereas if only GDF15 was induced (n=11), 64% of histology findings were normal. 
Normal biomarkers associated with no diagnostic findings in muscle histology in 74% (either 
normal or mild unspecific) (Figure 2D).  
 
Then we compared the diagnostic performance of the biomarkers versus muscle histology (and 
OXPHOS enzyme analysis, if available) in those patients (n=20) who had genetically verified 
mitochondrial disease and biopsy and biomarker taken <6-12 months apart. Seventy percent of 
these patients (14/20) had FGF21 and/or GDF15 values intermediate or high and would have 
been identified as a likely to have a mitochondrial disease based on serum biomarker analysis 
only compared to 50% of patients who could have been identified with muscle biopsy. Three 
patients (15%) would only have been diagnosed by analyzing the muscle [two patients with 
mutations in mitochondrial ATPase subunit 6 (MTATP6): one with high amount of COX 
negative fibers, the other with decreased oxygen production in OXPHOS analysis. Third patient 
had neurogenic changes in histology caused by defect in mitofusin 2 (MFN2)]. Three patients 
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had normal-range biomarker values and the muscle histology was judged as either normal or 
only non-specific changes.  
 
Figure 3 summarizes the performance of muscle histological analysis in identifying a 
mitochondrial disease [children (n=61) and adults (n=66); muscle and serum sample taken less 
than 6-12 months apart]. A total of 44 children (72%) had no or mild unspecific changes in their 
muscle even though four of them had genetically verified mitochondrial disorder (Figure 3A). In 
adults, histological analysis showed no or mild unspecific findings and the OXPHOS analysis 
was normal in 30 (45%) of whom four had a genetically verified mitochondrial disorder (Figure 
3B). Taken together, 58% of patients in this prospective cohort had no clear changes in the 
muscle histological or biochemical analysis. Of the patients with pathological muscle histology 
findings (n=53), 34% were considered to have a non-mitochondrial disease, but two were 
actually later found to have mitochondrial diseases (mutations in MFN2 and MT-TH).  Thirty-
five patients were evaluated to have histological findings suggestive for a mitochondrial disorder, 
of whom 14 got a genetic diagnosis, 10 were indeed verified to be mitochondrial and four non-
mitochondrial diseases (Figure 3A-B). Some of these genetic diagnoses (mutations in SARS2, 
MT-ATP6 and MT-TL1) were also found in patients whose muscle biopsy sample showed no 
evident changes.  
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We studied 194 patients with a suspected mitochondrial disorder, of whom 173 were investigated 
prospectively, as part of a routine diagnostic protocol. We compared the diagnostic yield of 
serum biomarkers FGF21 and GDF15 to the established modalities of routine diagnostic 
histological and biochemical analysis of muscle.  We did not standardize the muscle biopsy 
analyses but wanted to compare the realistic diagnostic situation to biomarkers FGF21 and 
GDF15.  We found that 58% of the muscle biopsy samples provided no diagnostic conclusion 
showing no or only non-specific changes (Figure 3). In contrast, analysis of FGF21 and GDF15 
identified 62% of patients with genetically verified mitochondrial disease, and 82% of those with 
muscle manifesting mitochondrial disease. Of the patients with mitochondrial diseases, who had 
no diagnostic findings in the muscle sample, elevation of the serum biomarkers pointed to 
mitochondrial disease in 69% patients. Only four patients had normal biomarker values, despite 
having mitochondrial abnormalities in their muscle biopsy (Table 3C). 
 
This prospective cohort study confirmed that the induction of FGF21 and GDF15 is highly 
restricted to muscle-manifesting disorders caused by defects in mtDNA expression.15 Pure 
mitochondrial encephalopathies without muscle involvement usually showed normal values. Our 
cohort included mitochondrial diseases in which these biomarkers have not previously been 
studied. These included - mitochondrial aspartyl-tRNA synthetase 
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deficiency/leukoencephalopathy with brain stem and spinal cord involvement and lactate 
elevation (DARS2); mitochondrial DNA depletion syndrome 13 (FBXL4); axonal, type 2A2 
Charcot-Marie-Tooth disease (MFN2); combined oxidative phosphorylation deficiency 15 
(MTFMT); mitochondrial complex I deficiency (NDUFV2), and  spastic paraplegia 7 (SPG7)  
 
Our prospective data showed that induction of biomarkers FGF21 and GDF15 clusters to patients 
with symptoms and findings typical for mitochondrial disorders (Supplementary tables 1 and 2). 
Previously, out of a total of 69 patients with both biomarkers analyzed,15-17 only two patients 
with a non-mitochondrial disorder had induction of both biomarkers (one with inclusion body 
myositis (IBM) and another with myotonic dystrophy type II). One patient with Alagille 
syndrome (deletion in chromosome 20p12.1-p11.23) had both biomarkers highly induced, which 
may be due to the large chromosomal aberrations including mitochondrial-targeted genes or to 
be secondary to severe cardiac disease. Overall, the findings are consistent with GDF15 and 
FGF21 having high specificity to mitochondrial disease group.  
 
Our findings showed that in more than half of the muscle biopsies taken, the histological or 
OXPHOS activity analysis had no clear diagnostic value, particularly in children. If we had 
standardized the muscle evaluation and evaluated both histology and biochemistry thoroughly in 
every patient, the diagnostic yield could have been somewhat bigger but we wanted to include 
the authentic reports from the patients in this prospective study, and the results indicate the 
This article is protected by copyright. All rights reserved.
Lehtonen et al.    
 
difficulty of mitochondrial diagnoses. Sometimes the findings are not completely logical, and 
genetic findings are not always easy to interpret. Mitochondrial disease diagnosis is challenging, 
the analysis of skeletal muscle is not standardized in different laboratories, and biochemical 
analyses of OXPHOS even less. This is why more biomarkers that are straight forward to do in 
different, even not specialized laboratories, are required, such as serum ELISA analysis of 
FGF21 and GDF15.  
 
Induction of FGF21 and GDF15 was highly restricted to muscle-manifesting mitochondrial 
diseases caused by mitochondrial translation defect or mtDNA deletions. FGF21 and GDF15 
have good positive predictive values for these disorders, direct further diagnostic procedures, are 
inexpensive to measure, and the risk of complications is minor compared to surgical muscle 
biopsy. We therefore propose that the serum biomarkers FGF21 and GDF15 together be used as 
first-line diagnostic tools in patients with muscle involvement, but can be used in all patients 
with a suspicion of mitochondrial disease, although in pure encephalopathies biomarkers often 
remain normal. Normal biomarker values do not, rule out a mitochondrial disorder, especially if 
the disease does not manifest in muscle, but if at least one of biomarkers is elevated, the next 
diagnostic examination could be next-generation sequencing analysis of mitochondrial disease 
genes, both mitochondrial and nuclear DNA. This approach would speed up the diagnostic rate 
of mitochondrial diseases, bring the diagnostic modalities to everyday use, as well as reduce the 
This article is protected by copyright. All rights reserved.
Lehtonen et al.    
 
need of invasive muscle biopsies, and minimizing the risk of complications. Further, biomarkers 
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Figure 1. Patient categorization flowchart. 194 patients participated to the study, of which 173 
were studied prospectively. Numbers indicate the number of patients. 
Abbreviations: dg= diagnosis; mo= months; mito= mitochondrial disease; non-mito= non-
mitochondrial disease. 
 
Figure 2. Findings of muscle biopsy sample compared to serum biomarkers (A-D) and 
genetic etiology. Correlation of biomarker values to muscle biopsy findings in 127 patients (A-D) 
with muscle sample taken close (<6-12 months apart) to the serum sampling. Induction of 
biomarker equals to FGF21 >331pg/ml and GDF15 >1014pg/ml. Histopathological findings of 
muscle biopsy samples in all 164 biopsied patients (E) of which 33 had genetically verified 
mitochondrial (F) and 20 non-mitochondrial (G) disease.  
 
Figure 3. Matching of the genetic etiology to findings of muscle biopsy sample and 
OXPHOS analysis in those 127 patients, whose muscle biopsy and serum sampling were 
taken <6-12 months apart. A: Pediatric patients (age at biopsy <16 years), B: Adult patients 
(age at biopsy ≥16 years). 
Abbreviations: HPD=histopathological diagnosis, OXPHOS=oxidative phosphorylation, dg= 
diagnosis, mito= mitochondrial disorder, non-mito= non-mitochondrial disorder, MM= 
mitochondrial myopathy, *= pathogenicity unverified.  
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Characteristic Number of 
patients 
(percent) 





≥ 16 (considered as adults in this study) 
 
 17    (9) 
 37   (19) 
 22   (11) 
 12    (6) 
106  (55) 
Sex 
      Male 
      Female 
 
 84   (43) 
110  (57) 
 
Clinical diagnosis 
      Myopathy 
          (PEO 6, generalized myopathy 76) 
      Encephalo(myo)pathy (Leigh, Alpers, MELAS   etc.) 
      Ataxia (incl. IOSCA) 
      Peripheral neuropathy 
      Multi-organ disease  
      Cardiomyopathy 
      Other (incl. MIDD) 
 
  
 82   (42) 
 
 70   (36) 
 17    (8) 
  9     (5) 
  7     (4) 
  2     (1) 
  7     (4) 
Disease with diabetes    8     (4) 
Disease with cardiac manifestation   9     (5) 
Disease with renal manifestation   - 
Disease with liver manifestation   5     (3) 
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Table 2. Categorization of A) mitochondrial and B) non-mitochondrial disease genes and 
the FGF21 and GDF15 values of the patients. The cut-offs are based on Lehtonen et al 2016, 
the 95th percentile of control population and 95th percentile of non-mitochondrial myopathies. 
HGNC (HUGO Gene Nomenclature Committee) approved gene symbols are used. Biomarker 
concentrations are as pg/ml. Number in parenthesis indicates number of patients if more than one. 
One patient had both MT-TV and MT-RNR1 mutations. ΔmtDNA indicates heteroplasmic single 
large scale mitochondrial DNA deletion. 
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Table 3. FGF21, GDF15, age, phenotype, muscle sample findings in patients with genetically verified mitochondrial disease  
Clinical myopathy defined as muscle weakness, PEO, ptosis, exercise intolerance or rhabdomyolysis. HGNC (HUGO Gene 
Nomenclature Committee) approved gene symbols are used. 
 
3A. Both FGF21 (>331 pg/ml) and GDF15 (>1014 pg/ml) elevated. 
FGF21 GDF15 Gene * Age (years) Phenotype 
Clinical 
myopathy Muscle biopsy 
RC 
deficiency 
2455 2761 mtDNA deletion (90% m) 21 PEO + COX-negative fibers na 
396 1441 POLG 56 Mitochondrial spinocerebellar ataxia (MSCA) + COX-negative fibers na 
1232 4074 mtDNA deletion (50% m) 64 myopathy + ”mitochondrial myopathy” CI 
398 4735 MT-TL1 (na) 60 MELAS - fat droplets in EM - 
456 1231 mtDNA deletion (50% m) 52 PEO + 
ragged blue fibers, 
increased staining SDH 
of the cellborders 
CI,CV 
504 1328 SPG7 59 ataxia, mental deterioration, deafness, cardiomyopathy - RRF 
CI, O2 
consumption 
912 2152 mtDNA deletion (60% m) 60 PEO + COX-negative fibers, RRF - 
1956 7601 MT-TL1 (80% m) 24 MELAS + abnormal cristae and mitochondria in EM CI 
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878 2802 MT-TK (93% m) 34 encephalopathy - RRF CI,CV 
642 1833 MT-TL1 (90% u) 39 MELAS + normal na 
826 2868 MT-TL1 (26% m) 30 myopathy + RRF, abnormal cristae in EM 
CI, O2 
consumption 
2170 4868 MT-TL1 (70%, na) 43 MELAS/MIDD + uninformative - 





3B. Either FGF21 (>331pg/ml) or GDF15 (>1014pg/ml) elevated. 
FGF21 GDF15 Gene Age (years) Phenotype 
Clinical 
myopathy Muscle biopsy 
RC 
deficiency 
628 884 POLG 59 PEO  + COX -negative fibers,  mild type 2 fiber atrophy  na 
304 1074 POLG 41 Mitochondrial spinocerebellar ataxia (MSCA) + na na 
332 769 POLG 43 Mitochondrial spinocerebellar ataxia (MSCA) + na na 
260 1362 MT-TL1 (19% m) 30 exercise intolerance, PEO + normal CI 
286 2074 MT-TL1 (62% m) 61 MELAS - “mitochondrial myopathy” CIV 
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262 1311 POLG 38 Alpers syndrome - ragged red fibers O2 consumption 
408 384 MT-TV and MT-RNR1 (na) 2 infantile neuroaxonal dystrophy - normal na 
342 816 MT-TL1 (57% m) 35 MELAS + ”mitochondrial myopathy” - 
284 2528 POLG 23 myopathy + unspecific - 
68 3208 SARS2 0 encephalomyopathy, congenital lactic acidosis + normal 
CI-CV, O2 
consumption 
198 1624 MT-ND5 (61% m) 2 Leigh(-like) syndrome - normal CI, O2 consumption 
24 2618 FBXL4 0 cardio-encephalomyopathy + normal - 
96 1528 TWNK 65 IOSCA - na na 
 
 












Muscle biopsy RC deficiency 
4 328 DARS2 10 LBSL na na na 
260 232 MFN2 15 peripheral neuropathy + unspecific - 
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44 344 MFN2 13 peripheral neuropathy - na na 
44 298 MFN2 13 peripheral neuropathy - na na 
239 870 MT-ATP6 (na)**   32 cardio-encephalomyopathy, myelodysplastic syndrome + 




74 348 MT-ATP6 (100% m) 3 NARP / Leigh - unspecific - 
160 624 MT-ATP6 (95% m, 96% f) 1 failure to thrive, poor growth - unspecific ATP production 
244 294 MT-FMT (na) 21 Leigh-like encephalomyopathy + na CI, CIII 
258 566 MT-TL1 (28% m) 33 MELAS - COX-negative fibers, RRF na 
234 784 MT-TL1 (10% m) 53 MELAS + normal - 
202 326 NDUFV2 11 Leigh syndrome - na na 
98 289 SARS2 9 encephalopathy - unspecific - 
270 278 TWNK 31 IOSCA - na na 
120 559 TWNK 38 IOSCA - na na 
163 716 TWNK 41 IOSCA - na na 
190 323 TWNK 2 IOSCA - na na 
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 *For mitochondrial DNA mutations, the amount of mutant mitochondrial DNA (per cent) and the tissue studied are in parentheses. 
Abbreviations: b=blood; CFTD= congenital fiber type disproportion; COX = cytochrome c oxidase; f=fibroblasts; IOSCA= infantile-
onset spinocerebellar ataxia; m= muscle; MELAS= mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; 
NARP= neurogenic ataxia and retinitis pigmentosa; LBSL= leucoencephalopathy with brainstem and spinal cord involvement and lactate 
elevation; MM= mitochondrial myopathy; na= not available; RC deficiency= respiratory chain deficiency (in muscle); RRF= ragged red 
fibers; u= urine; += yes, - = no. ** Novel mtATP6 mutation, unverified. 
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